contrast agent p792 profile

contrast agent P792: a gadolinium macrocyclic compound based on a Gd-DOTA structure substituted by hydrophilic arms; rapid clearance blood pool agent for magnetic resonance imaging; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	91668170
MeSH ID	M0399194

Synonym
hydrogen (2,2',2',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-triyl)tetrakis(5-((2-((4-((4-((2-((3,5-bis(bis((2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl-2,4,6-tribromo)carbamoyl)phenyl)amino)-2-oxoethyl)carbamoyl)phenyl)carbamoyl)phenyl)amino)-2-oxoethyl)
p792 ,
unii-lf24366z4o
contrast agent p792

Excerpt	Reference	Relevance
" The safety controls consisted of complete pre- and postdose physical examinations, measurement of vital signs, clinical laboratory investigations, and monitoring of adverse events (up to 22 days after injection)."	( Safety and pharmacokinetics of p792, a new blood-pool agent: results of clinical testing in nonpatient volunteers. Bonnemain, B; Chassard, D; Gaillard, S; Kubiak, C; Stolz, C, 2002)	0.31
"No serious adverse events occurred during the study."	( Safety and pharmacokinetics of p792, a new blood-pool agent: results of clinical testing in nonpatient volunteers. Bonnemain, B; Chassard, D; Gaillard, S; Kubiak, C; Stolz, C, 2002)	0.31
"P792 appeared to be a safe and well-tolerated RCBPA in nonpatient subjects."	( Safety and pharmacokinetics of p792, a new blood-pool agent: results of clinical testing in nonpatient volunteers. Bonnemain, B; Chassard, D; Gaillard, S; Kubiak, C; Stolz, C, 2002)	0.31

Excerpt	Reference	Relevance
" As a result of this high molecular volume, P792 presents an unusual pharmacokinetic profile, as it is a Rapid Clearance Blood Pool Agent (RCBPA) characterized by limited diffusion across the normal endothelium."	( P792: a rapid clearance blood pool agent for magnetic resonance imaging: preliminary results. Corot, C; Dencausse, A; Devoldere, L; Idée, JM; Le Greneur, S; Meyer, D; Port, M; Raynal, I; Rousseaux, O; Simonot, C, 2001)	0.31
"To summarize the physicochemical characterization, pharmacokinetic behavior, and biological evaluation of P792, a new monogadolinated MRI blood-pool agent."	( Physicochemical and biological evaluation of P792, a rapid-clearance blood-pool agent for magnetic resonance imaging. Bonnemain, B; Corot, C; Dencausse, A; Idee, JM; Lancelot, E; Lautrou, J; Meyer, D; Port, M; Raynal, I, 2001)	0.31
" The pharmacokinetic and biodistribution profiles were studied in rabbits."	( Physicochemical and biological evaluation of P792, a rapid-clearance blood-pool agent for magnetic resonance imaging. Bonnemain, B; Corot, C; Dencausse, A; Idee, JM; Lancelot, E; Lautrou, J; Meyer, D; Port, M; Raynal, I, 2001)	0.31
" The pharmacokinetic and biodistribution profiles are consistent with that of a rapid-clearance blood-pool agent: P792 is mainly excreted by glomerular filtration, and its diffusion across normal endothelium is limited."	( Physicochemical and biological evaluation of P792, a rapid-clearance blood-pool agent for magnetic resonance imaging. Bonnemain, B; Corot, C; Dencausse, A; Idee, JM; Lancelot, E; Lautrou, J; Meyer, D; Port, M; Raynal, I, 2001)	0.31
" The pharmacokinetic and biodistribution profiles are consistent with those of a rapid-clearance blood-pool agent."	( Physicochemical and biological evaluation of P792, a rapid-clearance blood-pool agent for magnetic resonance imaging. Bonnemain, B; Corot, C; Dencausse, A; Idee, JM; Lancelot, E; Lautrou, J; Meyer, D; Port, M; Raynal, I, 2001)	0.31
" For pharmacokinetic analysis, the determination of P792 was performed using the ICP-MS technique for blood and urine samples up to 22 days."	( Safety and pharmacokinetics of p792, a new blood-pool agent: results of clinical testing in nonpatient volunteers. Bonnemain, B; Chassard, D; Gaillard, S; Kubiak, C; Stolz, C, 2002)	0.31
"Due to its physicochemical and pharmacokinetic properties, P792 allows the use of a reduced dosage of gadolinium, resulting in less T2* effect without compromising T1 enhancement."	( Renal functional contrast-enhanced magnetic resonance imaging: evaluation of a new rapid-clearance blood pool agent (p792) in sprague-dawley rats. Claudon, M; Corot, C; Felblinger, J; Grenier, N; Mandry, D; Odille, F; Pedersen, M; Robert, P, 2005)	0.33
"A physiological pharmacokinetic (PBPK) model was used to estimate tumor microcirculation in nude mice with a grafted tumor."	( Evaluation of antiangiogenic treatment effects on tumors' microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging. Balvay, D; Bessoud, B; Bois, FY; Brochot, C; Cuénod, CA; Siauve, N, 2006)	0.33

Excerpt	Relevance	Reference
"3) or half dosage (65."	( Renal functional contrast-enhanced magnetic resonance imaging: evaluation of a new rapid-clearance blood pool agent (p792) in sprague-dawley rats. Claudon, M; Corot, C; Felblinger, J; Grenier, N; Mandry, D; Odille, F; Pedersen, M; Robert, P, 2005)	0.33
"Due to its physicochemical and pharmacokinetic properties, P792 allows the use of a reduced dosage of gadolinium, resulting in less T2* effect without compromising T1 enhancement."	( Renal functional contrast-enhanced magnetic resonance imaging: evaluation of a new rapid-clearance blood pool agent (p792) in sprague-dawley rats. Claudon, M; Corot, C; Felblinger, J; Grenier, N; Mandry, D; Odille, F; Pedersen, M; Robert, P, 2005)	0.33

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	27 (77.14)	29.6817
2010's	5 (14.29)	24.3611
2020's	3 (8.57)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (8.11%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	34 (91.89%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
histamine [no description available]	2	1	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
meglumine Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.. N-methylglucamine : A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, while its antimonate is used as an antiprotozoal in the treatment of leishmaniasis.	3.11	5	hexosamine; secondary amino compound
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.72	3	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
triphenyltetrazolium triphenyltetrazolium: RN given refers to parent cpd. 2,3,5-triphenyltetrazolium : An organic cation that is tetrazole carrying three phenyl substituents at positions 2, 3 and 5.	2.03	1	organic cation
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	2.03	1	C-nitro compound; imidazoles	antitubercular agent
sulfur hexafluoride Sulfur Hexafluoride: Sulfur hexafluoride. An inert gas used mainly as a test gas in respiratory physiology. Other uses include its injection in vitreoretinal surgery to restore the vitreous chamber and as a tracer in monitoring the dispersion and deposition of air pollutants.. sulfur hexafluoride : A sulfur coordination entity consisting of six fluorine atoms attached to a central sulfur atom. It is the most potent greenhouse gas currently known, with a global warming potential of 23,900 times that of CO2 over a 100 year period (SF6 has an estimated lifetime in the atmosphere of between 800 and 3,000 years).	2.05	1	sulfur coordination entity	greenhouse gas; NMR chemical shift reference compound; ultrasound contrast agent
gadolinium Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.	3.62	9	f-block element atom; lanthanoid atom
pimonidazole pimonidazole: structure given in first source	2.03	1
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.42	2	1,2,3-triazole
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	2.07	1	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate: RN refers to Na salt	3.63	9
zd 6474 CH 331: structure in first source	2.04	1	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor
leukotriene b4 Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.	2	1	dihydroxy monocarboxylic acid; hydroxy polyunsaturated fatty acid; leukotriene; long-chain fatty acid	human metabolite; mouse metabolite; plant metabolite; vasoconstrictor agent
gadolinium dtpa Gadolinium DTPA: A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)	2.44	2	gadolinium coordination entity	MRI contrast agent
cediranib [no description available]	2.04	1	aromatic ether
gadofosveset trisodium gadofosveset trisodium: a low molecular weight molecule chelated to Gadolinium, that strongly binds to plasma proteins; Vasovist is an injectable for imaging the vascular system by magnetic resonance angiography	2.42	2
piperidines Piperidines: A family of hexahydropyridines.	2.04	1

Condition	Relationship Strength	Studies	Trials
Brain Hemorrhage [description not available]	2.6	1	0
Apoplexy [description not available]	2.6	1	0
Acute Ischemic Stroke [description not available]	2.6	1	0
Hemorrhage, Subarachnoid [description not available]	2.6	1	0
Ischemic Stroke Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.	2.6	1	0
Subarachnoid Hemorrhage Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.	2.6	1	0
Intracranial Hemorrhages Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces.	2.6	1	0
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	2.6	1	0
Gestational Hypertension [description not available]	3.99	1	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	3.89	2	1
Hypertension, Pregnancy-Induced A condition in pregnant women with elevated systolic (	3.99	1	1
Hepatocellular Carcinoma [description not available]	2.04	1	0
Experimental Hepatoma [description not available]	2.04	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.04	1	0
Angiogenesis, Pathologic [description not available]	2.94	4	0
Cancer of Pancreas [description not available]	2.06	1	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.06	1	0
Cancer of Lung [description not available]	2.07	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.07	1	0
Colorectal Cancer [description not available]	2.46	2	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.96	4	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.46	2	0
Carcinoma, Anaplastic [description not available]	2.07	1	0
Cancer of Cervix [description not available]	2.07	1	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2.07	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2.07	1	0
Cancer of Prostate [description not available]	2.01	1	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.01	1	0
Benign Neoplasms, Brain [description not available]	2.01	1	0
Glial Cell Tumors [description not available]	2.01	1	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.01	1	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.01	1	0
Cardiovascular Stroke [description not available]	2.94	4	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	2.94	4	0
Breast Cancer [description not available]	2.02	1	0
Experimental Mammary Neoplasms [description not available]	2.02	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.02	1	0
Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)	2.03	1	0
Benign Neoplasms [description not available]	2.03	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.03	1	0
Chronic Illness [description not available]	2.03	1	0
Cicatrization The formation of fibrous tissue in the place of normal tissue during the process of WOUND HEALING. It includes scar tissue formation occurring in healing internal organs as well as in the skin after surface injuries.	2.03	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.03	1	0
Cicatrix The fibrous tissue that replaces normal tissue during the process of WOUND HEALING.	2.03	1	0
Cancer of Colon [description not available]	2.04	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.42	2	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.04	1	0
Atherogenesis [description not available]	2.03	1	0
Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.	2.03	1	0
Acute Kidney Failure [description not available]	2	1	0
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	2	1	0

contrast agent p792

Description

Cross-References

Synonyms (4)

Research Excerpts

Toxicity

Pharmacokinetics

Dosage Studied

Research

Studies (35)

Market Indicators

Research Demand Index: 10.83

Study Types